J
Joachim von Pawel
Researcher at University of Texas MD Anderson Cancer Center
Publications - 144
Citations - 27028
Joachim von Pawel is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 52, co-authored 142 publications receiving 25012 citations.
Papers
More filters
Molecular biomarkers in non-small-cell lung cancer : a retrospective analysis of data from the phase 3 FLEX study
Kenneth J. O'Byrne,Ulrich Gatzemeier,Igor Bondarenko,Carlos H. Barrios,Corinna Eschbach,Uwe M. Martens,Yevhen Hotko,Cornelius Kortsik,Luis Paz-Ares,José Rodrigues Pereira,Joachim von Pawel,Rodryg Ramlau,Jae Kyung Roh,Chih Teng Yu,Christopher Stroh,Ilhan Celik,Armin Schueler,Robert Pirker +17 more
TL;DR: The FLEX study as discussed by the authors showed that the addition of cetuximab to cisplatin and vinorelbine significantly improved overall survival in the first-line treatment of EGFR-expressing, advanced non-small-cell lung cancer.
Journal ArticleDOI
P-569 The relationship between treatment-free interval (TFI) and outcomes to therapy in patients with relapsed Small Cell Lung Cancer (SCLC): A review of 631 patients treated with IV topotecan in 6 studies
Joachim von Pawel,Andrea Ardizzoni,Nick Thatcher,T. Crofts,Paul Wissel,Graham Dane,Graham Ross +6 more
Journal ArticleDOI
Lobaplatin (D-19466) in Patients with Advanced Non-Small-Cell Lung Cancer: A Trial of the Association for Medical Oncology (AIO) Phase II Study Group
Christian Manegold,P. Drings,U. Gatzemeier,Joachim von Pawel,Heinz H. Fiebig,Wolfgang Queisser,Lutz Edler +6 more
TL;DR: Lobaplatin was well tolerated when applied as a 50 mg/m2 single bolus intravenously in 4-week intervals and was only marginally effective in the dose and schedule used, providing no support for further use of this treatment plan in patients with NSCLC.
Journal ArticleDOI
CA184-156: Randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus placebo plus EP in patients (Pts) with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC).
Joachim von Pawel,Sang-We Kim,David R. Spigel,Christoph C. Zielinski,Maria Catherine Pietanza,Veerle de Pril,Marc S. Ballas,Martin Reck +7 more
TL;DR: A randomized Phase 2 study of Ipi with paclitaxel/carboplatin in pts with ED-SCLC showed significant improvement in progression-free survival (PFS), as measured by irRC, over PC alone in pts receiving Ipi and PC in a phased regimen.